27 авг. 2018 г. · GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary ...

28 окт. 2019 г. · Description: The goal of the trial was to evaluate 1 month of aspirin plus ticagrelor followed by 23 months of ticagrelor monotherapy ...

The objective of the current analysis of GLOBAL LEADERS is to compare the efficacy and safety of monotherapy with ticagrelor and aspirin amongst those patients ...

17 сент. 2021 г. · In the GLOBAL LEADERS trial, the experimental regimen consisting of ticagrelor and aspirin DAPT for 1 month, followed by ticagrelor monotherapy ...

21 сент. 2021 г. · The experimental strategy was 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy.

The GLOBAL LEADERS trial was an Investigator-Initiated Study (IIS) in which 16,000 “all-comer” patients were enrolled in 130 centers in 18 countries in Europe, ...

The GLOBAL LEADERS trial aims to assess the role of ticagrelor as a single antiplatelet agent after a short course of DAPT for the long-term prevention of ...

26 сент. 2019 г. · The GLOBAL LEADERS trial was a randomized, open-label superiority trial conducted at 130 sites in 18 countries. The formal trial protocols are ...

1 мар. 2022 г. · In the GLOBAL LEADERS trial, ticagrelor monotherapy beyond 1 month compared with standard antiplatelet regimens after coronary stent ...

Информация об этой странице недоступна. ·